Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Study objective:
This is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound complications such as infection, wound rupture or seroma, or if it may increase the risk of blood clots.
Eligible patients:
Patients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery.
Study intervention:
Participants will receive a single local application of study drug onto their wound surfaces at the end of surgery. Study drug will be identical looking ampoules which contain either TXA or placebo (saline). Neither participants nor study personnel will know the contents of the ampoules.
Full description
Any serious postoperative complication needing intervention, specifically re-bleeding, wound infection, wound rupture, or the occurrence of blood clots for the first 30 days after surgery will be registered through the following interventions:
Screening of patient medical records Distribution of an electronic self-report form (eForsk®) to participating patients at postoperative day 30 Follow-up phone call to verify data after day 30.
The study is terminated after the final phone call. All study data will be registered in an electronic, pseudonymous web-based registration form (eCRF/Viedoc®).
Number of participants: To assess the effect of TXA on the defined surgical complications compared to placebo, 1500 patients are needed in each group.
Data monitoring committee:
A data monitoring committee consisting of a group of independent scientists will be appointed for this study to monitor the safety and scientific integrity of this human research intervention.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients are eligible to be included in the study only if all of the following criteria apply:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
3,000 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Kjersti Ausen, MD PhD; Olav Spigset, MD PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal